Entry Details

About the Entry

Category: 
Online > Online Industry News Coverage > Upper Midwest

Title of entry: 
BioSpace: Making Sense of Biopharma’s Ups and Downs

Issue or Publication date:
October 28, 2024; May 27, 2024; October 1, 2024; November 4, 2024; December 2, 2024; October 9, 2024

Publication name: 
BioSpace

View Website home page:
https://www.biospace.com/

Links to entry URLs

Please note: These URLs are only required for entries in the Online division categories, or digital entries in appropriate Overall Excellence, Design or All Content division categories.

Entry URL(s), if applicable:
Please enter a URL that will direct judges to the entry: 
https://www.biospace.com/fda/evolving-fda-accelerated-approval-pathway-suffers-spate-of-withdrawals
Additional URLs, if needed:
https://www.biospace.com/who-will-the-next-big-pharma-players-be
https://www.biospace.com/drug-development/the-making-of-bms-cobenfy-from-alzheimers-to-schizophrenia
https://www.biospace.com/drug-development/car-t-and-related-therapies-home-in-on-autoimmune-disease
https://www.biospace.com/drug-development/biopharma-takes-on-deadly-brain-cancer-after-decades-of-failure
https://www.biospace.com/business/lillys-sprawling-obesity-clinical-program-underscores-challenges-for-biotechs

Entry Essay: 
At BioSpace, we pride ourselves on our comprehensive coverage of major events and emerging trends in the biopharma industry. From researchers to regulators to C-suite executives, industry professionals rely on BioSpace for up-to-the-minute news and unique perspectives on a range of issues, including the overall health of the sector, hot new drug classes, strategic business decisions and changing policies and legal decisions. We dissect the implications of these developments for our readers’ work and careers.

One overarching area of our coverage in 2024 was the increased scrutiny on the FDA’s accelerated approval program, especially as drugs recently greenlit through this pathway have been withdrawn from the market. Of our many stories on this topic, our first entry is a feature that looks at the evolution of the program over the past 30 years, the therapeutic possibilities it enables and the challenges still to overcome. The story includes commentary from Joel Perlmutter, a vocal critic of the pathway who resigned from an FDA advisory board after one such approval.

BioSpace also extensively covers the billions of dollars that flow through the biopharma industry. In May 2024, pharma giant AstraZeneca set a massive annual revenue target of $80 billion, prompting us to take a deep dive into market caps of the biggest pharmaceutical companies—and the large biotechs that could one day soon be considered part of the Big Pharma club.

As for the science that underlies innovation in this industry, BioSpace prioritizes coverage of the most compelling disease areas and therapeutic classes. In our third entry, we unpack the history of the first new schizophrenia treatment in 35 years and the first-ever approval of a muscarinic receptor agonist. Cobenfy, for which Bristol Myers Squibb received market approval in September, actually began as an Alzheimer’s drug candidate at Eli Lilly. We spoke with key players along the drug’s development pathway, chronicling a serendipitous discovery.

Turning to the revolutionary technology of cell and gene therapy, our fourth story explores the pivot of CAR T therapy, already a breakthrough in cancer treatment, to autoimmune conditions. In this in-depth piece, we spoke with companies and scientific experts about how these engineered immune cells could be leveraged against lupus, myasthenia gravis and more.

We also included a feature that surveys the companies making headway in treating glioblastoma, a deadly brain cancer that has long stumped drug developers. One of our most popular stories of the year, this article touches on a variety of therapeutic classes and demonstrates the multifaceted approach it takes to address major unmet medical needs for patients with intractable diseases.

Finally, while neuroscience and oncology draw significant biopharma investment and feature prominently in our coverage, the hottest space in biopharma right now is undoubtedly obesity. As an example of our comprehensive coverage of this sector, we included a data-driven piece illustrating the dominance of Eli Lilly—and rival Novo Nordisk—that could make it hard for up-and-comers in the space.